European patent specification

(19) NO

NORWAY ^{(51) Int Cl.}

C12N 7/01 (2006.01)

A61K 39/12 (2006.01)

C07H 21/00 (2006.01)

C07K 14/00 (2006.01)

C07K 14/08 (2006.01)

Norwegian Industrial Property Office

(21) Translation Published 2018.06.04

(80) Date of The European

Patent Office Publication of

the Granted Patent 2018.02.28

(86) European Application Nr. 09805653.4

(86) European Filing Date 2009.08.10

(87) The European Application’s

Publication Date 2011.05.25

(30) Priority 2008.08.08, US, 87504 P

2009.06.19, US, 218603 P

(84) Designated Contracting

States: AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ;

IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; SM ; TR

(73) Proprietor Takeda Vaccines, Inc., 75 Sidney Street, Cambridge, MA 02139, US-USA (72) Inventor RICHARDSON, Charles, c/o Takeda Vaccines, Inc.75 Sidney Street, Cambridge,

MA 02139, US-USA

BARGATZE, Robert, c/o Takeda Vaccines, Inc.75 Sidney Street, Cambridge, MA 02139, US-USA

HAYNES, Joel, c/o Takeda Vaccines, Inc.75 Sidney Street, Cambridge, MA 02139, US-USA

STEADMAN, Bryan, c/o Takeda Vaccines, Inc.75 Sidney Street, Cambridge, MA 02139, US-USA

(74) Agent or Attorney BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54) Title VIRUS-LIKE PARTICLES COMPRISING COMPOSITE CAPSID AMINO ACID SEQUENCES FOR ENHANCED CROSS REACTIVITY

(56) References

Cited: WO-A1-93/21325, WO-A1-2008/042789, WO-A2-2006/086188, US-A- 5953727, US-A1- 2007

207526, CACHIA P J ET AL: "THE USE OF SYNTHETIC PEPTIDES IN THE DESIGN OF A CONSENSUS SEQUENCEVACCINE FOR PSEUDOMONAS AERUGINOSA", JOURNAL OF PEPTIDE RESEARCH, BLACKWELL PUBLISHING LTD, OXFORD; GB, vol.52, no.4, 1 October 1998 (1998-10-01), pages 289-299, XP000781730, ISSN: 1397-002X, Foubert, TR et al.: "Preclinical Development of a Broad Spectrum Norovirus Vaccine.", 2009 AAPS National /ExpoNBC09/CC/forms/attendee/index.aspx?co ntent=sessionInfo&sessionId=150 [retrieved on 2011-11-14], MCBURNEY SEAN P ET AL: "Developing broadly reactive HIV-1/AIDS vaccines: a review of polyvalent and centralized HIV-1 vaccines.", CURRENT PHARMACEUTICAL DESIGN 2007 LNKD- PUBMED:17627529, vol.13, no.19, 2007, pages 1957-1964, XP002663633, ISSN: 1873-4286, WANG C Y ET AL: "Effective synthetic peptide vaccine for foot-and-mouth disease in swine", VACCINE, ELSEVIER LTD, GB, vol.20, no.19-20, 7 June 2002 (2002-06-07), pages 2603-2610, XP004359694, ISSN: 0264-410X, DOI: 10.1016/S0264-410X(02)00148-2, MUTHUMANI K ET AL: "Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus", VACCINE, ELSEVIER LTD, GB, vol.26, no.40, 14 April 2008 (2008-04-14), pages 5128-5134, XP025349960, ISSN: 0264-410X [retrieved on 2008-04-14], US-B1- 7067 638

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/